Category: Gene therapy

Advancements in gene therapy have brought hope to individuals with Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle weakness. While breakthroughs like adeno-associated virus (AAV) gene therapy have shown promise, significant hurdles still impede the path to widespread efficacy and safety. The Quest for Improved Gene Therapy in DMD DMD, stemming […]

Foamy virus (FV) vectors hold promise for gene therapy due to their unique features, but low titers have hindered large-scale clinical trials. A study aimed to boost FV vector titer by 50-fold through innovative vector plasmids and enhanced transfection methods. The vectors successfully transduced human CD34+ cells, leading to high engraftment frequencies in immunodeficient mice. […]

In the realm of gene therapy, the demand for scalable and efficient production systems for adeno-associated virus (AAV) vectors is escalating rapidly. The OneBac platform emerges as a groundbreaking solution, offering scalable and genetically stable recombinant AAV (rAAV) production for the full spectrum of AAV serotypes 1–12. Developed with the vision of Dr. Regine Heilbronn […]

VectorY Therapeutics has entered into a significant collaboration with Shape Therapeutics, focusing on evaluating the potential of SHP-DB1, a specialized capsid developed by Shape, in delivering therapies to the brain. This partnership holds immense promise for VectorY’s developmental treatments for Huntington’s and Alzheimer’s diseases, aiming to leverage Shape’s innovative adeno-associated virus (AAV) capsid technology for […]

In the realm of cell and gene therapies, where innovation dances with complexity, there lies a delicate balance to be struck. Clayton Irvine, a maestro of pharmaceutical orchestration with his PharmD, MBA, MS ensemble, conducts a symphony of value-based access by harmonizing standardized care protocols, seamless transitions between care realms, meticulous evaluation of prior authorizations, […]

In the intricate realm of gene therapy, vectors play a seductive role, beckoning with promises of transformative treatments for a myriad of ailments. Both viral and non-viral vectors dance in a delicate balance, each offering unique strengths and challenges as they navigate the intricate pathways of genetic medicine. These vectors, akin to skilled couriers, hold […]

In the annals of scientific history, a somber chapter is inscribed on September 17, 1999—a date marking the first reported death attributed to gene therapy. Nestled within the hallowed halls of the University of Pennsylvania, a tragic event unfolded, shrouding the promising field of gene therapy in a veil of caution and skepticism for the […]

A tectonic shift is palpable in the biopharma realm, with the White House contemplating stringent regulations on drug imports from Chinese biotechs, prompting major players like Sanofi and Merck to divest from the U.K. post imposition of substantial levies. Simultaneously, Novo Nordisk, under the new leadership of CEO Maziar Mike Doustdar, undertakes a significant workforce […]

Critics have recently raised concerns over Sarepta’s gene therapy, Elevidys, designed for treating Duchenne muscular dystrophy. While the safety of Elevidys has been under scrutiny, the focus has now shifted towards questioning the therapy’s efficacy and how it is being measured. A group of prominent researchers has highlighted a crucial aspect that demands attention: the […]

Eli Lilly’s groundbreaking weight loss treatment, Orforglipron, is on the cusp of becoming the inaugural drug to be fast-tracked under the FDA’s innovative approval program, showcasing a pathway to expedited access for patients in need. Orforglipron, an experimental GLP-1 from Eli Lilly and Company, holds the potential to be swiftly ushered through the approval process […]

Cell culture media play a crucial role in the field of gene therapy production, specifically tailored to support the growth, viability, and productivity of cells involved in manufacturing gene therapy products like viral vectors. These specialized media are distinct from general-purpose ones due to the stringent requirements for safety, yield, and regulatory compliance in gene […]

A recent analyst survey indicates that despite safety concerns surrounding Sarepta’s Elevidys gene therapy, doctors are still prescribing it, particularly to ambulatory patients, showcasing confidence in its risk-benefit profile. BMO Capital Markets’ survey of 30 physicians revealed that approximately 90% of them continue to prescribe Elevidys, focusing on ambulatory patients following regulatory scrutiny due to […]

Real-world evidence (RWE) utilization in health plan decision-making for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) treatments is currently limited due to the lack of standardized evaluation frameworks and the legal obligation for payers to justify coverage decisions with established clinical evidence. Health plans often consider RWE as supplementary rather than primary decision-making data, especially for […]

Introduction Escherichia coli strains engineered for antibiotic-free plasmid selection and maintenance are revolutionizing biotechnology applications such as gene therapy and recombinant protein production. This article delves into the innovative construction of two novel E. coli strains, DH1lacdapD and DH1lacP2dapD, that allow for the antibiotic-free selection and stable maintenance of recombinant plasmids through repressor titration, a […]

The realm of cancer gene therapy is poised for a remarkable evolution, set to catapult the global market to unprecedented heights. Witnessing a meteoric rise from a humble US$ 1.74 billion in 2021, the market is projected to soar exponentially, reaching a staggering US$ 12.4 billion by the year 2030. This phenomenal growth trajectory, boasting […]

Cartherics, an innovative Australian biotechnology company, has recently clinched the prestigious title of ‘Most Promising iPSC Therapy Pipeline in APAC’ at the highly acclaimed Asia Pacific Cell and Gene Therapy Excellence Awards 2025 in Singapore. This remarkable achievement not only solidifies Cartherics’ position as a frontrunner in the realm of cell and gene therapy but […]

In the ever-evolving landscape of biotechnology, the plasmid DNA manufacturing market stands at the forefront of innovation and growth. The demand for advanced therapeutics, especially in areas like oncology, has propelled the market to new heights, with a projected CAGR of 14.85% through 2035. This surge is fueled by the expansion of cell and gene […]

In a recent and devastating blow to the UK life sciences sector, pharmaceutical giant MSD has announced the abandonment of its £1 billion expansion project in the country. The decision to halt the construction of a state-of-the-art facility in London and the subsequent layoffs of 125 employees has sent shockwaves through the industry, underscoring the […]

MSD’s recent decision to withdraw from a £1 billion investment program in the UK has sparked reactions from various stakeholders. The UK government is now striving to reignite negotiations on drug pricing and rebates, aiming to salvage the situation post the breakdown of talks last month. Health Secretary Wes Streeting is leading this effort amidst […]

Syncona, a pioneering investment manager, is at the forefront of shaping the next generation of global leaders in the life science industry. With a diversified portfolio spanning various clinical stages, Syncona’s mission is centered on maximizing value and revolutionizing patient outcomes. Through strategic investments and active management, the company aims to drive significant growth in […]

The DNA methylation market is on a trajectory of remarkable growth, projected to surge from USD 1.9 billion in 2025 to a staggering USD 7.7 billion by 2035, boasting a robust compound annual growth rate of 15.0%. This unprecedented surge underscores the pivotal role of epigenetics in revolutionizing clinical diagnostics, personalized medicine, and translational research, […]

Zentiva, a prominent generics company, is on the brink of a significant transition as reports surface of a €4.1 billion acquisition by US investment group GTCR from current owner Advent International. This impending deal marks the second private equity transfer of a European drugmaker this month, hinting at a dynamic shift within the pharmaceutical landscape. […]

The quest for effective treatments for Duchenne muscular dystrophy (DMD) has witnessed significant advancements in genetic therapies like AAV9-based gene therapy and CRISPR programs. However, recent clinical setbacks emphasize the need for a diversified approach that includes small molecules, cell therapies, and advanced biologics to accelerate progress and impact in treating DMD patients. Heading Towards […]

A groundbreaking study by an international team of researchers has shed light on a previously unrecognized mechanism by which the widely used breast cancer drug tamoxifen can elevate the risk of secondary tumors in the uterus. This discovery challenges existing beliefs about therapy-related cancers and underscores how drug actions can supplant genetic changes in tumor […]

Gene Therapy Marks a Turning Point for Rare Skin Diseases In the realm of medical breakthroughs, gene therapy has emerged as a revolutionary treatment for rare skin diseases, offering a beacon of hope to those afflicted. This innovative approach signifies a shift from merely managing symptoms to actively repairing the genetic anomalies that underlie these […]

Introduction: Ferring Pharmaceuticals, a pioneering biopharmaceutical company dedicated to enhancing lives and fostering familial well-being, recently received approval from the PMDA Japan for the New Drug Application (NDA) of nadofaragene firadenovec. This groundbreaking gene therapy, already launched in the United States, presents a paradigm shift in the treatment of non-muscle invasive bladder cancer (NMIBC). The […]

The U.S. Food and Drug Administration recently unveiled a groundbreaking initiative called the Rare Disease Evidence Principles (RDEP). This new framework is designed to streamline and expedite the review process for therapies targeting rare diseases, particularly those with very small patient populations. In an effort to enhance speed and predictability, the FDA aims to provide […]

Menopause is a natural phase in a woman’s life, signifying the end of her reproductive years. However, a recent survey conducted across six countries shed light on the unfortunate reality of menopause discrimination in the workplace. More than a third of women reported experiencing negative impacts at work due to menopause, with some even stating […]

AbbVie, a biopharmaceutical giant, witnessed a remarkable surge of 4.4% in its stock value following a pivotal legal settlement with generic drug manufacturers regarding its flagship autoimmune medication, Rinvoq. This agreement secured an additional 12 years of exclusive rights for Rinvoq in the United States until April 2037, shielding it from generic competition and propelling […]

Neuromuscular diseases present ongoing challenges to clinicians, especially in refractory forms like myasthenia gravis (MG), characterised by fluctuating muscle weakness due to pathogenic autoantibodies targeting neuromuscular junctions. Current treatments, while innovative, only achieve complete disease control in a subset of patients, highlighting the need for more targeted immunotherapies. CAR-T cell therapy shows promise in eliminating […]

AbbVie, a prominent pharmaceutical company, has recently triumphed in the battle to delay generic competition for its flagship drug, Rinvoq, until 2037. This victory has sparked a surge in AbbVie’s share prices as it settles litigation with various generic drugmakers, ensuring continued market exclusivity for Rinvoq in the United States. The company’s success in extending […]

The recent tragic incident involving a child’s death after receiving an experimental gene therapy for STXBP1 encephalopathy has shed light on the complexities and challenges of developing treatments for rare neurological disorders. Capsida Biotherapeutics, the company behind the gene therapy, is among the pioneers in engineering viruses to deliver genes into the brain safely. Despite […]

Capsida Biotherapeutics recently faced a tragic event with the death of a patient who received their gene therapy CAP-002 for STXBP1-related epileptic encephalopathy disorders. The exact cause of death has not been disclosed, prompting Capsida to pause the study and collaborate with the FDA to investigate further. This incident underscores the critical need for continuous […]

In the realm of non-muscle invasive bladder cancer (NMIBC), a groundbreaking shift is underway with the introduction of gene therapy. This innovative approach offers a promising solution for patients who do not respond to traditional BCG treatments. With quarterly dosing regimens that significantly reduce treatment burden, gene therapy has demonstrated impressive response rates ranging from […]

Novo Nordisk, a key player in the biopharmaceutical industry, recently faced FDA scrutiny at its Bloomington, IN facility. This plant, acquired through the Catalent buyout, received an FDA Form 483 due to issues related to contamination, pest infestations, and equipment failures. The FDA’s findings pointed out cases of contamination by unusual particles like cat and […]

The cell and gene therapy industry has shown remarkable progress, with the approval of the first CRISPR-based gene therapy in the US in 2023. Former President Joe Biden hailed this advancement for its potential in treating rare diseases. However, recent developments have brought a shift towards a more realistic outlook on the industry, exemplified by […]

Scientists have recently introduced innovative tests capable of swiftly and accurately detecting avian influenza, commonly referred to as bird flu. These new tests are proving to be instrumental in monitoring the virus in animals and the environment, with a particular focus on wastewater surveillance. The highly pathogenic avian influenza A(H5N1) has caused significant devastation in […]

Gene editing therapy, such as exagamglogene autotemcel (exa-cel), has demonstrated significant improvements in the quality of life for patients with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia. These advancements are crucial in the field of gene therapy, particularly as they directly impact patients’ daily lives by enhancing physical, social, functional, and emotional well-being. […]

Creative Biogene has recently unveiled its groundbreaking adeno-associated virus (AAV) vector platform, signaling a pivotal moment in the realm of gene therapy innovation. This move comes at a time when the demand for effective gene therapies is escalating, underscoring the critical need for efficient and reliable vector solutions to drive advancements in research and clinical […]

Gene therapy is emerging as a promising approach to enhance the compatibility of brain implants by altering neurons. Merge Labs, a company that has piqued the interest of prominent figures like Sam Altman, is exploring the use of gene therapy to make neurons more receptive to brain implants. The concept involves sensitizing neurons to ultrasound […]

Gene therapy has shown significant promise in addressing critical medical needs, with successful clinical trials driving investments in drug development. Notable successes include gene replacement for diseases like Hemophilia B, X-linked Severe Combined Immunodeficiency, and Leber’s Congenital Amaurosis Type 2, as well as cancer immunotherapy trials using chimeric antigen receptor T cells. The approval of […]

Sarepta Therapeutics, a biotech company, has been at the center of a turbulent story revolving around their gene therapy for Duchenne muscular dystrophy. Amidst the excitement and disappointment surrounding this therapy, a lesser-known group of patients with limb-girdle muscular dystrophy has found themselves left behind in the pursuit of a treatment breakthrough. Families like Rachel […]

Gene therapy for rare diseases, like p47 Chronic Granulomatous Disease, presents a groundbreaking opportunity to revolutionize treatment options for patients facing life-limiting conditions. The recent development of the world’s first gene therapy for p47 CGD by UCL and GOSH underscores the immense potential of this innovative approach in providing life-changing solutions for individuals with rare […]

Sarepta Therapeutics (NASDAQ: SRPT) has undergone significant transformations in recent months, particularly following critical safety incidents impacting non-ambulatory Duchenne Muscular Dystrophy (DMD) patients. These events have prompted a strategic shift away from gene therapy towards RNA-based technologies. This shift has raised concerns among investors and analysts, leading to a recent rating downgrade for the company. […]

The White House and the European Union have recently reached a significant trade agreement that imposes a 15% cap on pharmaceutical tariffs, set to come into effect on September 1. This deal, emphasizing reciprocal and fair trade practices, covers all imports from the EU, with specific regulations governing pharmaceutical products. Under this agreement, the United […]

Genprex, Inc., a leading gene therapy company dedicated to revolutionizing cancer and diabetes treatments, has recently achieved a significant milestone by securing patents in the United States and Europe for their innovative gene therapy, Reqorsa, in conjunction with PD-L1 and PD-1 antibodies. The US Patent and Trademark Office has granted a Notice of Allowance covering […]

Gene Therapy Specialist Kriya recently raised an impressive $313.3 million in funding to support its innovative pipeline of gene therapies targeting various chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes. The company’s lead asset, KRIYA-825, has shown promising results in preclinical studies and is set to enter clinical trials for geographic […]

A groundbreaking development in the treatment of sickle cell disease has emerged, bringing hope to individuals like 22-year-old Daniel Cressy, who is set to be the first person in Louisiana to undergo a gene therapy aimed at curing the disease. This significant milestone, chronicled by journalist Emily Woodruff, is the culmination of extensive research spanning […]

In a groundbreaking presentation at the 2025 annual scientific meeting of the American Society of Retina Specialists, Dr. Omer Trivizki unveiled the first-time results of VOY-101, a pioneering gene therapy designed to address geographic atrophy (GA) by modulating the complement system. This innovative therapy, aimed at non-neovascular patients, has shown exceptional safety and tolerability in […]

SpliceBio, a genetic medicines company centered on Protein Splicing to combat diseases stemming from mutations in large genes, has successfully closed a $135 million Series B financing round. The funding, co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors, aims to drive the clinical development of SB-007, […]

Taysha Gene Therapies recently underwent scrutiny from 11 analysts, offering a diverse range of perspectives from optimistic to pessimistic views. Analyst evaluations in the last quarter revealed an average 12-month price target of $9.00, with a high estimate of $14.00 and a low estimate of $6.00, marking a 14.65% increase from the previous average target […]

In the dynamic landscape of gene therapy, Ferring Pharmaceuticals emerges as a standout player with its remarkable success in commercializing a bladder cancer gene therapy, Adstiladrin. While many gene therapies struggle to gain traction in the market despite their curative potential, Ferring has defied the odds by securing a strong launch for Adstiladrin, positioning it […]

Abeona Therapeutics, a biotech company specializing in cell and gene therapies for rare diseases, recently reported its Q2 2025 earnings, showcasing a significant milestone with a positive net income driven by a one-time asset sale rather than ongoing business activities. The quarter marked the company’s first revenue recognition, despite no therapeutic product sales, as the […]

Fujifilm and HORIBA have collaborated on a cutting-edge gene delivery system that promises to revolutionize the production of gene therapy products. Through Fujifilm’s breakthrough continuous electroporation technology, which enhances gene delivery efficiency by up to 100 times compared to traditional methods, the new system aims to significantly boost productivity in manufacturing gene therapies. This advancement […]

UC Davis has been awarded a significant $3.6 million grant by the National Eye Institute for pioneering research in gene therapy for ocular conditions. The focus of this research lies in exploring a novel, minimally invasive approach to deliver gene therapy directly into the suprachoroidal space of the eye. This space, situated between the eye’s […]

Children with spinal muscular atrophy (SMA) have shown promising motor function improvements when transitioning to onasemnogene abeparvovec after receiving prior treatment with nusinersen or risdiplam, as revealed in a recent real-world study. This study, published in Neuromuscular Disorders, highlighted the significant motor function enhancement observed in SMA patients who shifted to onasemnogene abeparvovec following initial […]

The advancement and widespread adoption of cell and gene therapies have ushered in a new era of personalized, life-saving treatments. However, this progress has brought about unique challenges in quality control testing. Traditional methods are often inadequate in assessing the dynamic and sensitive nature of these therapies, necessitating the development of innovative and agile testing […]

SineuGene Therapeutics Co., Ltd., a clinical-stage biotechnology firm specializing in gene therapies for neurological disorders, has received approval from both the National Medical Products Administration (NMPA) in China and the Food and Drug Administration (FDA) in the United States for their Investigational New Drug (IND) application for SNUG01. This groundbreaking gene therapy product is designed […]

Klotho Neurosciences, a biotechnology company, has recently embarked on the manufacturing and development of its gene therapy candidate, KLTO-202, utilizing the cutting-edge platform technology of AAVnerGene Inc. This collaboration marks a significant milestone for Klotho, leveraging AAVnerGene’s expertise in adeno-associated viruses (AAV) manufacturing and targeted delivery systems. The innovative approach involves harnessing a human gene […]

Amidst the COVID-19 pandemic, Medicare Advantage (MA) plans have generally outperformed traditional Medicare (TM) in clinical quality measures, but during the pandemic, TM narrowed the gap on certain in-person screenings. A retrospective cohort study analyzed over 3 million Medicare beneficiaries from 2017 to 2021, dividing them into TM and MA cohorts in 2019 (pre-pandemic) and […]

Adeno-associated viruses (AAVs) play a crucial role in gene therapy by delivering foreign DNA into cells. The characteristics of different AAV serotypes, such as cell binding and transduction abilities, are largely influenced by the structure of their capsid viral proteins. A study focused on AAV serotype 4 (AAV4), known for its diverse capsid protein sequence […]

Cell and gene therapy manufacturing face significant hurdles due to outdated processes hindering their advancement. Despite the substantial investments and excitement surrounding these cutting-edge therapies, the manufacturing operations often lag behind in terms of innovation and efficiency. The sector’s rapid growth within the life sciences industry brings to light the need to address the unique […]

An investigational gene therapy, EXG001-307, developed by Exegenesis Bio, has shown promising results in improving motor function in a mouse model of spinal muscular atrophy (SMA). Compared to the approved SMA gene therapy Zolgensma, EXG001-307 demonstrated a better safety profile with fewer adverse effects on the animals’ hearts. This allowed for higher doses to be […]

Market challenges persist in the gene therapy space, despite the promising potential these treatments offer as curative solutions. Sarepta Therapeutics’ experience with Elevidys, a Duchenne muscular dystrophy therapy, exemplifies this struggle. Following a controversial approval in 2023, revenue for Elevidys soared to $820 million in the past year. However, a safety concern raised by the […]

In recent years, Moldavia has been actively involved in the export licensing of viral vectors, crucial components in gene therapy and vaccine development processes. The shift towards the NewVectorLicense Model signifies a significant milestone in the country’s regulatory framework. This model aims to streamline and modernize the licensing process, ensuring compliance with international standards and […]

Gene therapy holds great promise in revolutionizing medical treatments, particularly for rare and genetic diseases. The Komi Republic gene therapy trials have been pivotal in advancing our understanding of this cutting-edge field. These trials have focused on various conditions, ranging from hemophilia to muscular dystrophy, offering hope to patients and their families. One of the […]

Pulmonary fibrosis (PF) poses a significant challenge in the realm of interstitial lung diseases, characterized by limited treatment options and unfavorable prognoses. Recent advancements in understanding PF pathogenesis have shed light on the intricate mechanisms driving the disease, emphasizing the crucial interplay between Western medical interventions and traditional Chinese medicine (TCM) as potential therapeutic avenues. […]

Ocugen is strategically positioning itself to revolutionize the gene therapy market for eye disorders by launching three new treatments for blindness-related diseases over the next three years, with two already in advanced clinical trials. The company is especially focused on its OCU400 modifier gene therapy, designed to address varying stages of retinitis pigmentosa (RP), a […]

Incorporating gene therapy into non-muscle invasive bladder cancer (NMIBC) treatment programs requires meticulous planning and execution. Establishing robust institutional protocols that align with current guidelines and clinical trial standards is crucial for successful implementation. Collaboration with industry partners can provide valuable training resources and insights to streamline the integration process and avoid common pitfalls associated […]

PET/CT imaging plays a vital role in predicting relapse and outcomes in patients with multiple myeloma (MM) undergoing chimeric antigen receptor (CAR) T-cell therapy, as per a recent publication in HemaSphere. The study suggests that utilizing PET/CT scans can help healthcare providers identify high-risk MM patients post-treatment, enabling tailored therapeutic strategies such as incorporating radiation […]

In a groundbreaking discovery by a team of researchers in South Korea, a potential paradigm shift in cancer treatment has emerged. By identifying and targeting three key genes – MYB, HDAC2, and FOXA2 – responsible for maintaining cancer cells in a malignant state, these scientists have found a way to reprogram these cells back to […]

Sarepta Therapeutics Inc. witnessed a significant surge in its stock value following the FDA’s reversal of its decision, allowing patients capable of walking to receive the Elevidys gene therapy once again. This change in stance by the US regulatory body came after a temporary halt in Elevidys shipments due to three deaths associated with Sarepta’s […]

4D Molecular Therapeutics, symbolized as FDMT, has recently been under the scrutiny of five financial analysts who have shared their viewpoints over the past three months. Their assessments varied from optimistic to pessimistic stances, reflecting a diversity of opinions on the company’s future prospects. Analyzing the recent ratings provided by these financial experts reveals a […]

Gene therapy manufacturing is undergoing a revolutionary shift, with cutting-edge technologies enhancing the production of crucial components such as AAV vectors. The measurement of the empty-full capsid ratio is identified as a Critical Quality Attribute (CQA) in AAV vector production, ensuring the reliability and efficacy of the process. Advanced ddPCR technology is instrumental in providing […]

In the second session of GEN’s ‘The State of CRISPR & Genome Editing’ virtual summit, held on June 11, 2025, Johnny Mahlangu, MMed, Director at Haemophilia Comprehensive Care Centre at University of the Witwatersrand, Johannesburg, South Africa, and Julie Makani, MD, PhD, Associate Professor in the Department of Hematology and Blood Transfusion at Muhimbili University […]

AGC Biologics’ Milan site continues to solidify its reputation as a global leader in cell and gene therapy with its recent 10th product approval from the EMA and FDA. With a 30-year track record of success, the team at AGC Biologics Milan has deep expertise in handling complex projects in the field. They have successfully […]

Gene therapy is a cutting-edge approach to treating genetic conditions and other diseases by introducing a healthy version of a specific gene. This method holds immense potential in revolutionizing medical treatment by addressing underlying genetic causes. Gene editing, a related technique, involves making precise changes to genes to correct mutations or introduce beneficial variations. Both […]

Recent breakthroughs in gene therapy have shown promising results in the treatment of inflammatory skin diseases such as psoriasis. While mild cases can be managed with traditional medications, severe symptoms often require systemic drugs with potential side effects. Gene therapy offers a targeted approach by modifying the patient’s genes to address the root cause of […]

Exciting advancements have been made in the field of stem cell therapy with promising data emerging from the first human trial. This progress offers hope for a new approach to Alzheimer’s care, potentially aiding in the healing process of the brain rather than just slowing the disease progression. The Phase 1 study is focused on […]